A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia

International Journal of Neuropsychopharmacology

Volumn 13, Issue 4, 2010, Pages 451-460

  Lane, Hsien Yuan ^a,b   Lin, Ching Hua ^c   Huang, Yu Jhen ^a   Liao, Chun Hui ^a   Chang, Yue Cune ^d   Tsai, Guochuan E ^e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c KAI SUAN PSYCHIATRIC HOSPITAL   (Taiwan)

^d TAMKANG UNIVERSITY   (Taiwan)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

D serine; Glycine; N methylglycine; NMDA; Sarcosine; Schizophrenia

Indexed keywords

DEXTRO SERINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SARCOSINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; INSOMNIA; MALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; TENSION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PLACEBOS; QUALITY OF LIFE; SARCOSINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SERINE; STEREOISOMERISM;

EID: 77953545879     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990939     Document Type: Article

References (57)

1. Andreasen NC (1983). Scales for the Assessment of Negative symptoms (SANS). University of Iowa: Iowa City, IA.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC.
3. APA (1995). Structured Clinical Interview for DSM-IV. American Psychiatric Press: Washington, DC.
4. Barnes TRE (1989). A rating scale for the drug-induced akathesia. British Journal of Psychiatry 154, 672-676.
5. Bergeron R, Meyer T, Coyle J, Greene R (1998). Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proceedings of the National Academy of Sciences USA 95, 15730-15734.
6. Buchanan RW, Javitt DC, Marder SR, Schooler NR, et al. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry 164, 1593-1602.
7. Chen L, Muhlhauser M, Yang CR (2003). Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. Journal of Neurophysiology 89, 691-703.
8. Coyle JT (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Review of Psychiatry 3, 241-253.
9. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, et al. (1989). A 'glutamatergic hypothesis' of schizophrenia: rationale for pharmacotherapy with glycine. Clinical Neuropharmacology 12, 1-13.
10. Eschenbrenner M, Jorns MS (1999). Cloning and mapping of the cDNA for human sarcosine dehydrogenase, a flavoenzyme defective in patients with sarcosinemia. Genomics 59, 300-308.
11. Glorieux FH, Scriver CR, Delvin E, Mohyuddin F (1971). Transport and metabolism of sarcosine in hypersarcosinemic and normal phenotypes. Journal of Clinical Investigation 50, 2313-2322.
12. Goff DC, Herz L, Posever T, Shih V, et al. (2005). A six month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berlin) 179, 144-150.
13. Goff DC, Tsai G, Levitt J, Amico E, et al. (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 56, 21-27. (Pubitemid 29055046)
14. Gomeza J, Hulsmann S, Ohno K, Eulenburg V, et al. (2003). Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron 40, 785-796.
15. Green MF, Nuechterlein KH, Gold JM, Barch DM, et al. (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 56, 301-307.
16. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare: Washington, DC.
17. Harding CO, Williams P, Pflanzer DM, Colwell RE, et al. (1992). Sar: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis. Proceedings of the National Academy of Sciences USA 89, 2644-2648.
18. Heinrichs DW, Hanlon TE, Carpenter WT (1984). The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10, 388-398.
19. Herdon HJ, Godfrey FM, Brown AM, Coulton S, et al. (2001). Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 41, 88-96.
20. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, et al. (2004). High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry 55, 165-171.
21. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, et al. (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. American Journal of Psychiatry 159, 480-482.
22. Heresco-Levy U, Javitt DC (2004). Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophrenia Research 66, 89-96.
23. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, et al. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 57, 577-585.
24. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, et al. (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 169, 610-617.
25. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, et al. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 56, 29-36.
26. Javitt DC (1987). Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia. Hillside Journal of Psychiatry 9, 12-35.
27. Javitt DC (2008). Glycine transport inhibitors and the treatment of schizophrenia. Biological Psychiatry 63, 6-8.
28. Javitt DC, Balla A, Burch S, Suckow R, et al. (2004). Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29, 300-307.
29. Javitt DC, Balla A, Sershen H, Lajtha A (1999). A. E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biological Psychiatry 45, 668-679.
30. Johnson KW, Clemens-Smith A, Nomikos G, Davis R, et al. (2003). In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors. Annals of the New York Academy of Sciences 1003, 412-414.
31. Karasawa J, Hashimoto K, Chaki S (2008). D-serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behavioural Brain Research 186, 78-83.
32. Kay SR, Opler LA, Fiszbein A (1987). Positive and negative syndrome scale (PANSS) manual. Schizophrenia Bulletin 13, 261-276.
33. Lane HY, Chang YC, Chiu CC, Lee SH, et al. (2004). Fine-tuning risperidone dosage for acute schizophrenia: clinical determinants. Psychopharmacology 172, 393-399.
34. Lane HY, Chang YC, Liu YC, Chiu CC, et al. (2005). Sarcosine (N-methylglycine) or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry 62, 1196-11024
35. Lane HY, Chiu WC, Chou JCY, Wu ST, et al. (2000). Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Journal of Clinical Psychiatry 61, 209-214.
36. Lane HY, Huang CL, Wu PL, Liu YC, et al. (2006). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological Psychiatry 60, 645-649.
37. Lane HY, Liu YC, Huang CL, Chang YC, et al. (2008). Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biological Psychiatry 63, 9-12.
38. Lange N, Ryan L (1989). Assessing normality in random effects models. Annals of Statistics 17, 624-642.
39. Lindenmayer JP, Bernstein-Hyman R, Grochowski S (1994). Five factor model of schizophrenia. Initial validation. Journal of Nervous and Mental Disorder 182, 631-638.
40. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, et al. (1987). The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 334 (Suppl.), 1-100.
41. Levy HL, Coulombe JT, Benjamin R (1984). Massachusetts metabolic disorders screening program: III. sarcosinemia. Pediatrics 74, 509-513.
42. Mart́nez-Chantar ML, Vázquez-Chantada M, Ariz U, Mart́nez N, et al. (2008). Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47, 1191-1199.
43. McBain CJ, Kleckner NW, Wyrick S, Dingledine R (1989). Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in xenopus Oocytes. Molecular Pharmacology 36, 556-565.
44. Rosnow RL, Rosenthal R (1996). Computing contrasts, effect sizes, and counternulls on other people's published data: general procedures for research consumers. Pyschological Methods 1, 331-340.
45. Shaw K, Turner J, Del Mar C (2002). Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Australian and New Zealand Journal of Psychiatry 36, 488-491.
46. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212 (Suppl.), 11-19.
47. Smith KE, Borden LA, Hartig PR, Branchek T, et al. (1992). Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8, 927-935.
48. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
49. Tsai G, Coyle JT (2001). Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology & Toxicology 42, 165-179.
50. Tsai G, Lane HY, Yang P, Chong MY, et al. (2004b). Glycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 55, 452-456.
51. Tsai G, Martina M, Bergeron R, Berger-Sweeney J, et al. (2004a). Gene knockout study of glycine transporter type 1. Proceedings of the National Academy of Sciences USA 101, 8485-8490.
52. Tsai G, Yang P, Chang Y, Chong M (2006). D-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 59, 230-234.
53. Tsai G, Yang P, Chung L, Lange N, et al. (1998). D-serine added to antipsychotic for the treatment of schizophrenia. Biological Psychiatry 44, 1081-1089.
54. Tsai GE, Yang P, Chung LC, Tsai IC, et al. (1999). D-serine added to clozapine for the treatment of schizophrenia. American Journal of Psychiatry 156, 1822-1825.
55. Williams RE, Lock EA (2004). D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism. Toxicology 201, 231-238.
56. Yen CH, Hung JH, Ueng YF, Liu SP, et al. (2009). Glycine N-methyltransferase affects the metabolism of aflatoxin B1 and blocks its carcinogenic effect. Toxicology and Applied Pharmacology 235, 296-304.
57. Zeger SL, Liang KY, Albert PS (1988). Models for longitudinal data: a generalized estimating equation approach. Biometrics 44, 1049-1060.